Value-Based Approach to Laboratory Requests — بوابة الرعاية الأولية

General considerations

Order labs with a clear clinical question in mind: if a result won't change your diagnosis or management, don't order it.
Consider pre-test probability: low probability of disease + non-specific symptoms → lab tests are more likely to give false positives than help.
Always review medical records to see if labs were recently ordered (avoid unnecessary repetition) and follow condition-specific policy for frequency.

Routine CBC is not needed as part of routine annual HTN or DM labs unless otherwise indicated.
May be part of annual follow-up in asymptomatic patients with high-risk chronic conditions (CKD, rheumatological disease, IBD).
Minimum intervals: Iron deficiency anemia — every 4–8 weeks until Hb normalizes, then repeat only if symptoms recur. Asymptomatic with normal CBC — don't order if done within 12 months.

Order only if symptomatic or clinically indicated.
In fatigue, counsel patients regarding missed causes: lifestyle (sedentary, overwork, dehydration), sleep (deprivation, poor hygiene, OSA), psychological (depression, anxiety, adjustment), and medical (uncontrolled chronic disease, medication side effects).
For persistent hair fall with normal workup, aim for ferritin >80; evaluate for telogen effluvium, traction, harsh products, and water quality.

RFT are diagnostic or monitoring tools — not screening tests in healthy asymptomatic patients.
For DM, HTN, or CKD risk monitoring: every 6–12 months if stable; more often if worsening or starting/changing therapy (ACEi, NSAIDs).
Always assess kidney function using estimated GFR (eGFR) rather than serum creatinine alone — a 'normal' creatinine can be misleading and mask early CKD.

LFTs are diagnostic or monitoring tools — not screening tests in healthy asymptomatic patients.
Clinical indications: unexplained jaundice, RUQ pain, suspected liver disease, monitoring hepatotoxic drugs (statins, methotrexate), abnormal imaging.
Frequency: every 3–6 months on hepatotoxic medications. Otherwise guided by clinical course (elevated enzymes → recheck in 2–4 weeks).

TFT are diagnostic or monitoring tools — not screening tests in healthy asymptomatic patients, except first antenatal visit.
Indications: symptoms suggestive of thyroid disease (other than fatigue alone), new AF or unexplained HF, goiter or nodules, infertility, monitoring known disease or replacement therapy.
Frequency: stable hypothyroid on therapy — every 6–12 months. After dose adjustments — recheck TSH after 6 weeks.

Routine testing not recommended as part of annual health check in asymptomatic low-risk adults.
Patients should be counseled that a daily 1,000 IU maintenance prevents repeated cycles of high-dose replacement and can treat mild deficiency (20–30 ng/mL).
Indications: osteoporosis/osteopenia, CKD stages 3–5, malabsorption, unexplained fractures/bone pain, certain medications (anticonvulsants, glucocorticoids).
Frequency: repeat once 3–6 months after starting supplementation in deficient patients; no routine repetition in stable patients.

Not routine in annual check in asymptomatic patients without risk factors.
Indications: macrocytic anemia (MCV >100), neurologic symptoms (paresthesia, neuropathy, ataxia, cognitive changes), malabsorption risk, long-term metformin or PPI use (>3–5 years), strict vegan diet.
Frequency: repeat once 2–3 months after starting treatment; no routine monitoring once stable unless symptoms recur.

Rarely indicated, except in specific cases like macrocytic anemia with normal B12 to distinguish folate deficiency, or in malabsorption.

Routine DM screening can be done with either FBG or HbA1C.
In-office fasting serum glucose is a rapid, inexpensive, valid diagnostic tool — widely underutilized.

DM screening — targeted groups

Age ≥35 years	All patients regardless of risk factors
Age <35 years	If BMI ≥25 (85th percentile in children) PLUS any DM risk factor

DM — frequency of re-testing & screening

Normal result	Every 3 years
Prediabetes	Yearly
History of GDM	Every 1–3 years
DM patient follow-up	Every 3–6 months (depends on control)

Lipid profile — targeted screening groups

Males ≥35, Females ≥45	All patients regardless of risk factors
Other age groups	If high-risk (diabetes, hypertension, smoking, obesity, family history of premature CVD)

Lipid profile — frequency

Normal & low-risk	Every 5 years
High-risk or abnormal (not on statins)	Every 1–3 years
Statins initiated	Recheck 4–12 weeks after starting or changing therapy. Once LDL-C at target → repeat every 6–12 months.

Emphasize personalized, evidence-based care with reassurance: every test is chosen carefully — not just because it's possible to order, but because it's truly proven to benefit the patient's health.
Explain how unnecessary tests can cause hidden harm with empathy: 'more tests' is not always better; unnecessary tests can show harmless variations that look abnormal, leading to stress, more appointments, and sometimes risky procedures.
Connect symptoms to tests with clarity and practical examples: focus on tests linked directly to history and exam findings.